Brokerages Set Humana Inc. (NYSE:HUM) Target Price at $297.68

Humana Inc. (NYSE:HUM - Get Free Report) has earned an average rating of "Hold" from the twenty-four ratings firms that are presently covering the firm, MarketBeat reports. Nineteen research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $297.68.

A number of brokerages have weighed in on HUM. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the company a "hold" rating in a research report on Monday, November 4th. Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Humana from $349.00 to $250.00 and set a "hold" rating on the stock in a report on Thursday, October 3rd. Leerink Partners lowered shares of Humana from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Finally, Piper Sandler raised their target price on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th.

Humana Price Performance

NYSE:HUM traded up $2.65 during trading hours on Thursday, hitting $296.88. 1,163,730 shares of the stock traded hands, compared to its average volume of 1,532,452. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The stock has a 50 day moving average price of $275.44 and a 200 day moving average price of $303.07. The company has a market cap of $35.75 billion, a price-to-earnings ratio of 26.30, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analysts' expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Sell-side analysts forecast that Humana will post 16.11 EPS for the current fiscal year.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company's stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.32% of the company's stock.

Institutional Investors Weigh In On Humana

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Atlas Brown Inc. increased its stake in shares of Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after acquiring an additional 38 shares during the last quarter. Moors & Cabot Inc. increased its position in Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after purchasing an additional 40 shares during the last quarter. Mather Group LLC. raised its stake in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after purchasing an additional 41 shares during the period. OLD National Bancorp IN boosted its holdings in Humana by 1.8% in the 3rd quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider's stock valued at $828,000 after purchasing an additional 45 shares during the last quarter. Finally, Your Advocates Ltd. LLP grew its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock valued at $32,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.